Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.…
Galectin Therapeutics (GALT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Galectin Therapeutics (NASDAQ: GALT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 9 employees.
The shares were at 2.690 USD on 20 November 2026, down 48.3% over 52 weeks. Its 52-week range is 2.030 USD to 7.130 USD: the price is 62.3% below the high and 32.5% above the low.
Its market capitalisation is 271.35M USD.
Galectin Therapeutics reports return on equity of 24.4% and an operating margin of 0.0%.
Its debt exceeds its cash by 27.15M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.